Navigation Links
Grunenthal Expands Use of BioClinica's Next Generation Trident IWR/IVR for Global Trial
Date:6/20/2013

NEWTOWN, Pa., June 20, 2013 /PRNewswire/ -- BioClinica®, Inc., a global provider of clinical trial management solutions, announced today that Grunenthal GmbH will again utilize the latest enhancements in Trident IWR/IVR for a global clinical study on pain medication. The three-year study will involve 350 patients at 80 sites across 17 countries. Trident streamlines the clinical trials process, making it faster and easier to set up, test, and deploy clinical study protocols.

(Logo:  http://photos.prnewswire.com/prnh/20130403/PH87647LOGO )

The integration of Trident into Grunenthal's clinical trial process is already underway. The new interactive web and voice response technology replaces a manual system for managing inventory, returns, and accountability of controlled substances. Trident automates these tasks and makes it easier to stay in compliance with controlled substance regulations, an especially important consideration for a pain management specialist.

In evaluating IVRs, no other technology provider met the controlled substance functionality Grunenthal needed. BioClinica responded by developing a customized solution. "BioClinica listened to our needs and built the functionality we needed into their IRT system in time for our deadline," said Henk Dieteren, Associate Director, Head Clinical Supply Manager, Compound Development and Branding, Clinical Development Operations, Clinical Trial Supply.  "We envision IRT systems becoming an integral part of our controlled substance studies," Dieteren added."Trident's ability to manage controlled substance inventory is crucial to meet strict regulatory requirements for conducting clinical trials that involve investigative compounds related to pain management."

The selection of Trident expands Grunenthal's use of BioClinica solutions, specifically OnPoint CTMS. In March 2012, the pharmaceutical company penned an agreement to use the customizable clinical trial management system enterprise-wide for gathering and sharing clinical trials information. Grunenthal made the selection recognizing OnPoint CTMS could help further innovation and development of new pain therapies.

"We are very pleased Grunenthal is expanding its use of BioClinica products to include Trident," said Peter Benton, BioClinica's President of eClinical Solutions. "The BioClinica suite of eClinical solutions is designed especially for this kind of integration, and will help Grunenthal manage its future clinical trials more efficiently."    

Trident reduces the average time it takes to write, set up, and validate IWR and IVR protocols from months to weeks. Trident supports all of a sponsor's clinical studies within a standardized data model that better supports automatic drug pooling and reporting.  By giving clinical trial sponsors the ability to monitor and maintain all their study protocols in one place, it is more efficient and cost-effective than developing specifications, programming and validating a new IWR system for each new study.

BioClinica is offering a free webinar on the subject of controlled substance studies titled Controlled Substance Studies: Meeting the Supply Management Challenge on August 8th, 2013 at 11:00 AM Eastern Time. BioClinica representatives will also be available to demonstrate the company's leading eClinical solutions at the Drug Information Association annual meeting June 24th through 26th in Boston, Massachusetts in Booth #1210.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About the Grunenthal GmbH

Grunenthal GmbH is an independent, family-owned international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus be a leader in therapy innovation. Altogether, Grunenthal GmbH has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and approximately 4,200 employees are working for Grunenthal GmbH globally. In 2011, Grunenthal achieved revenues of about 947M €. For more information: www.grunenthal.com.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. A 2013 merger with CoreLab Partners has created a new standard in imaging core lab services including electronic transfer, management, and independent review; cardiovascular safety monitoring including automated ECG, Thorough QT studies, Holter monitoring, ambulatory blood pressure monitoring and pulse wave analysis; and eClinical solutions for electronic data capture, randomization, clinical trial management, and clinical supply chain forecasting and optimization. BioClinica offers unmatched scientific expertise with a team of respected medical researchers and board certified, sub-specialty trained radiologists, cardiologists, nuclear medicine physicians and oncologists. With more than 28 years of experience and over 3,000 successful trials to date, BioClinica has supported the development of many new medicines through all phases of the clinical trial process. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide comprehensive cardiovascular safety, and eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.


'/>"/>
SOURCE BioClinica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerivet Solutions Expands to Manufacture Complex Metal Designs
2. Life Technologies Expands Range of Stem Cell Reprogramming Solutions
3. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
4. Senior Home Care Expands Home Health Telemonitoring into Spring Hill, Fla.
5. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
6. Sotera Wireless Expands Board Of Directors
7. NextDocs Expands Customer Roster by More Than 10 Percent
8. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
9. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
10. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
11. Fortune 500 Pharmaceutical Company Expands Use of inContact Cloud Contact Center Software Across Multiple Divisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/11/2019)... ... 2019 , ... SABRE , the leading brand in personal safety and ... showcase their latest and most innovative personal safety products, including the Mighty Discreet ... Summer Market 2019 (Booth #39158-UL), June 18-20 in Denver, CO. , SABRE’s ...
(Date:6/6/2019)... OAKLAND, Calif. (PRWEB) , ... June 06, 2019 , ... ... to further curtail US travel to Cuba. “This latest move is one more assault ... the island,” said Dr. Peter G. Bourne, Chair of MEDICC’s Board of Directors. ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of Health and ... Informatics (MSHI ) degree program to address the growing need for professionals who can ... of a larger effort for SHRS to bring more graduate degrees online. The Master ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive devices—are ... patient care. Children with birth defects, soldiers with cranial injuries, conjoined twins, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... with caregivers and dementia patients to deteriorate. , Researchers from the University ... survey with professional caregivers who care for people who have dementia and experienced ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... Miller, a quality assurance expert with more than 25 years of experience in ... Compliance for all classes of medical devices, has joined NDA Partners as an ...
(Date:6/12/2019)... ... 12, 2019 , ... In September of 2018, NVNA and Hospice (NVNA) partnered ... patient monitoring. Following its full-scale launch in March, NVNA has expanded its program with ... of 2019, NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and ...
Breaking Medicine News(10 mins):